AbbVie Inc. (ABBV)
After hours:
| Previous close | 163.79 |
| Open | 164.41 |
| Bid | 161.29 x 1200 |
| Ask | 162.50 x 1000 |
| Day's range | 161.00 - 164.63 |
| 52-week range | 130.96 - 182.89 |
| Volume | |
| Avg. volume | 5,702,121 |
| Market cap | 288.138B |
| Beta (5Y monthly) | 0.56 |
| PE ratio (TTM) | 48.43 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 6.20 (3.79%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
- PR Newswire
AbbVie to Present at the Bank of America Securities Healthcare Conference
AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, will present at 12:40 p.m. Central time.
- PR Newswire
AbbVie Reports First-Quarter 2024 Financial Results
AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2024.
- PR Newswire
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
AbbVie (NYSE: ABBV) today announced positive topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study that evaluated the efficacy and safety of upadacitinib (RINVOQ®, 15 mg once daily starting dose and dose-adjusted based on clinical response) versus dupilumab (DUPIXENT®, per its labeled dose) in adults and adolescents (≥12 years of age) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or when use of th
